Antibodies to TNF-α:: Too little, too late?

[1] EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12): : 934 - 941

[2] Abraham E, 1998, LANCET, V351, P929

[3] REPEATED ADMINISTRATION OF A F(AB')2 FRAGMENT OF AN ANTITUMOR NECROSIS FACTOR-ALPHA MONOCLONAL-ANTIBODY IN PATIENTS WITH SEVERE SEPSIS - EFFECTS ON THE CARDIOVASCULAR-SYSTEM AND CYTOKINE LEVELS [J]. SHOCK, 1994, 1 (04): : 237 - 245

[4] Effect of a chimeric antibody to tumor necrosis factor-α on cytokine and physiologic responses in patients with severe sepsis -: A randomized, clinical trial [J]. CRITICAL CARE MEDICINE, 1998, 26 (10) : 1650 - 1659

[5] CDP571, A HUMANIZED ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA - SAFETY, PHARMACOKINETICS, IMMUNE-RESPONSE, AND INFLUENCE OF THE ANTIBODY ON CYTOKINE CONCENTRATIONS IN PATIENTS WITH SEPTIC SHOCK [J]. CRITICAL CARE MEDICINE, 1995, 23 (09) : 1461 - 1469

[6] Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (05) : 311 - 315

[7] INFLUENCE OF AN ANTITUMOR NECROSIS FACTOR MONOCLONAL-ANTIBODY ON CYTOKINE LEVELS IN PATIENTS WITH SEPSIS [J]. CRITICAL CARE MEDICINE, 1993, 21 (03) : 318 - 327

[8] NATURAL CYTOKINE ANTAGONISTS AND ENDOGENOUS ANTIENDOTOXIN CORE ANTIBODIES IN SEPSIS SYNDROME [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (02): : 172 - 177

[9] MODULATION OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION BY TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) RELEASE IN THE COURSE OF PRETRANSPLANT CONDITIONING - ROLE OF CONDITIONING REGIMENS AND PROPHYLACTIC APPLICATION OF A MONOCLONAL-ANTIBODY NEUTRALIZING HUMAN TNF-ALPHA (MAK 195F) [J]. BLOOD, 1995, 86 (03) : 890 - 899

[10] Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study [J]. CRITICAL CARE MEDICINE, 1996, 24 (05) : 733 - 742

[1] EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12): : 934 - 941

[2] Abraham E, 1998, LANCET, V351, P929

[3] REPEATED ADMINISTRATION OF A F(AB')2 FRAGMENT OF AN ANTITUMOR NECROSIS FACTOR-ALPHA MONOCLONAL-ANTIBODY IN PATIENTS WITH SEVERE SEPSIS - EFFECTS ON THE CARDIOVASCULAR-SYSTEM AND CYTOKINE LEVELS [J]. SHOCK, 1994, 1 (04): : 237 - 245

[4] Effect of a chimeric antibody to tumor necrosis factor-α on cytokine and physiologic responses in patients with severe sepsis -: A randomized, clinical trial [J]. CRITICAL CARE MEDICINE, 1998, 26 (10) : 1650 - 1659

[5] CDP571, A HUMANIZED ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA - SAFETY, PHARMACOKINETICS, IMMUNE-RESPONSE, AND INFLUENCE OF THE ANTIBODY ON CYTOKINE CONCENTRATIONS IN PATIENTS WITH SEPTIC SHOCK [J]. CRITICAL CARE MEDICINE, 1995, 23 (09) : 1461 - 1469

[6] Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (05) : 311 - 315

[7] INFLUENCE OF AN ANTITUMOR NECROSIS FACTOR MONOCLONAL-ANTIBODY ON CYTOKINE LEVELS IN PATIENTS WITH SEPSIS [J]. CRITICAL CARE MEDICINE, 1993, 21 (03) : 318 - 327

[8] NATURAL CYTOKINE ANTAGONISTS AND ENDOGENOUS ANTIENDOTOXIN CORE ANTIBODIES IN SEPSIS SYNDROME [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (02): : 172 - 177

[9] MODULATION OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION BY TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) RELEASE IN THE COURSE OF PRETRANSPLANT CONDITIONING - ROLE OF CONDITIONING REGIMENS AND PROPHYLACTIC APPLICATION OF A MONOCLONAL-ANTIBODY NEUTRALIZING HUMAN TNF-ALPHA (MAK 195F) [J]. BLOOD, 1995, 86 (03) : 890 - 899

[10] Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study [J]. CRITICAL CARE MEDICINE, 1996, 24 (05) : 733 - 742